血清降钙素原在肺结核抗结核治疗疗效评估中的价值

Value of serum procalcitonin in anti-tuberculosis therapeutic effect evaluation for tuberculosis

目的研究血清降钙素原在肺结核抗结核治疗疗效评估中的价值。方法选择2012年1月－2013年1月本科诊治的肺结核患者为研究对象（观察组），以同期未行抗结核治疗的肺结核患者为对照（对照组），比较两组患者治疗前后血清降钙素原的水平并分析不同水平降钙素原抗结核治疗疗效差异。结果观察组和对照组肺结核患者治疗前血清降钙素原差异无统计学意义，观察组患者治疗后1个月、3个月和6个月血清降钙素原显著降低（P〈0．05），对照组治疗1个月、3个月和6个月血清降钙素原升高，观察组肺结核患者治疗1个月、3个月和6个月血清降钙素原均显著低于对照组（P〈0．05）。治疗前降钙素原水平显著升高、轻度升高和正常患者治愈率依次降低（P〈0．05）。结论肺结核患者血清降钙素原可作为其抗结核治疗疗效评估的标志物。

Objective To study the value of serum procalcitonin in anti-tuberculosis therapeutic effect evaluation for tuberculosis. Methods The patients with tuberculosis treated with anti-tuberculosis therapy in our department from January 2012 to January 2013 were selected as the observation group, while no anti-tuberculosis treatment patients with tuberculosis during the same period were selected as the control group. The level of serum procalcitonin in the two groups before and after the treatment were compared and the anti-tuberculosis therapeutic effect difference of different levels of procalcitonin were analyzed. Results There was not significant difference in the level of serum procalcitonin before the treatment between the observation group and the control group. The levels of serum procalcitonin in the observation group after the treatment of 1 month, 3 months and 6 months decreased significantly（P 〈 0.05）, while the levels of serum procalcitonin in the control group after the treatment of 1 month, 3 months and 6 months increased, and the levels of serum procalcitonin in the observation group after the treatment of 1 month, 3 months and 6 months were significantly lower than those in the control group（P 〈 0.05）.The cure rates of patients with significant elevated, mildly elevated and normal level of serum procalcitonin before the treatment reduced in turn（P 〈 0.05）. Conclusion Serum procalcitonin in patients with tuberculosis can as a sign of anti-tuberculosis therapeutic effect evaluation.